MedTrace Logo

Effect of F2695 on Functional Recovery After Ischemic Stroke

NCT01639014 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 532

Last updated 2015-04-01

No results posted yet for this study

Summary

The purpose of the study is to assess the efficacy of a new serotonin-norepinephrine reuptake inhibitor (SNRI) nin functional recovery after ischemic stroke.

Conditions

Interventions

DRUG

F2695

75 mg OD in 2 capsules

DRUG

placebo

2 capsules

Sponsors & Collaborators

  • Pierre Fabre Medicament

    lead INDUSTRY

Principal Investigators

  • François Chollet · Hôpital Purpan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • Belgium
  • Czechia
  • France
  • Germany
  • Hungary
  • Italy
  • Portugal
  • Russia
  • Spain
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01639014 on ClinicalTrials.gov